Navigation Links
Oncothyreon regains compliance with NASDAQ listing requirements
Date:3/16/2009

SEATTLE, March 16 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ONTY) (TSX: ONY), a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer, today announced that on March 12, 2009, it received a notice from the NASDAQ Hearings Panel that Oncothyreon had re-gained full compliance with the continued listing standards of The NASDAQ Global Market.

The notice followed a review of Oncothyreon's 2008 financial results, in which Oncothyreon reported that its stockholders' equity as of December 31, 2008 was $20,717,000. Based on this review, the staff of the NASDAQ Hearings Panel determined that Oncothyreon had regained compliance with the continued listing requirements in NASDAQ Marketplace Rule 4450 and notified Oncothyreon that the matter is now closed.

About Oncothyreon

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.

Forward-Looking Statements

In order to provide our investors with an understanding of our current condition and future prospects, this release contains statements that are forward-looking. These forward-looking statements include statements related to our ability to maintain compliance with the listing standards of The NASDAQ Stock Market. Forward-looking statements involve risks and uncertainties related to our business and the general economic environment, many beyond our control. These risks, uncertainties and other factors could cause our actual results to differ materially from those projected in forward-looking statements, including the risks associated with the availability and adequacy of financing, our financial condition and results of operations, general economic factors, achievement of the results we anticipate from our clinical trials with our products and our ability to adequately obtain and protect our intellectual property rights. Although we believe that the forward-looking statements contained herein are reasonable, we can give no assurance that our expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For a detailed description of our risks and uncertainties, you are encouraged to review the official corporate documents filed with the securities regulators in the United States on EDGAR and in Canada on SEDAR. Oncothyreon does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof.


'/>"/>
SOURCE Oncothyreon Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Oncothyreon to present at Invest Northwest 2009
2. Oncothyreon reports full year and fourth quarter 2008 financial results
3. Oncothyreon announces webcast of fourth quarter and year end 2008 financial results conference call
4. Oncothyreon to present at BIO CEO & Investor Conference 2009
5. Oncothyreon reports third quarter 2008 financial results
6. Oncothyreon to present at Rodman & Renshaw Annual Global Investment Conference
7. Oncothyreon announces November 6th webcast of third quarter 2008 financial results and corporate update conference call
8. Oncothyreon to present at BIO Investor Forum 2008
9. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
10. Oncothyreon announces prioritization plan for development programs
11. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... ... August 10, 2017 , ... SPIE, ... Company Ltd. as its exclusive sales representative for SPIE Journals in Japan. Kinokuniya ... SPIE Digital Library in Japan. , “We look forward to expanding our relationship ...
(Date:8/10/2017)... ... August 10, 2017 , ... ... AptaFluor SAH Methyltransferase Assay , an enabling new high throughput screening (HTS) ... that drive cancer and other debilitating diseases. , Chemical modification of gene expression, ...
(Date:8/8/2017)... ... 2017 , ... HumanZyme Inc., a leading supplier of novel ... launch of HumanKine® Interferon beta (IFN beta) expressed from HEK293 cells. ... innate immune responses against viral and bacterial infection, and have antiproliferative and immunomodulatory ...
(Date:8/8/2017)... ... 08, 2017 , ... Cynvenio Biosystems, Inc. a ... the launch of its second generation PD-L1 expression test. The new blood test ... sensitive and specific profiling and monitoring of PD-L1 expression on lung cancer cells ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/28/2017)... -- The report "Video Surveillance Market by ... Devices), Software (Video Analytics, VMS), and Service (VSaaS, Installation ... 2022", published by MarketsandMarkets, the market was valued at ... reach USD 75.64 Billion by 2022, at a CAGR ... considered for the study is 2016 and the forecast ...
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market is ... next decade to reach approximately $14.21 billion by 2025. ... all the given segments on global as well as regional levels ...
Breaking Biology News(10 mins):